Chronic food protein–induced enterocolitis syndrome: Characterization of clinical phenotype and literature review

Annals of Allergy, Asthma & Immunology

September 2016 Volume 117, Issue 3, Pages 227-233

Overall Purpose:
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:

Tamar Weinberger, MD (Author)

Elizabeth Feuille, MD (Author)

Cecilia Thompson, MD (Author)

Anna Nowak-Wegrzyn, MD (Author)

Jonathan A. Bernstein, MD (CME Subcommittee)

Guha Krishnaswamy, MD (CME Subcommittee)

Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)

Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the presentation, diagnosis and treatment of chronic FPIES
  • Recognize chronic FPIES early in its presentation in order to prevent complications 
Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, HRSA and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for GlaxoSmithKline, Meda, Mylan, and Teva; has received research grants from AstraZeneca, Bristol-Myers Squibb, Genentech, InterMune, Novartis, and Sunovion. J.A. Bernstein, G. Krishnaswamy, T. Weinberger, E. Feuille, C. Thompson, A. Nowak-Wegrzyn have nothing to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
09/01/2016
Course expires: 
08/31/2018
Cost:
$0.00

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
09/01/2016
Course expires: 
08/31/2018

Price

Cost:
$0.00
Please login or create an account to take this course.